Tarlatamab treatment for extensive stage small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and tolerability of subcutaneous tarlatamab in participants with extensive stage small cell lung cancer (ES-SCLC). The study involves administering tarlatamab to patients who have experienced disease progression after at least one line of platinum-based chemotherapy. Participants will be monitored for adverse effects and overall response to the treatment. The trial aims to gather data on the efficacy of this novel therapy in a challenging cancer type.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants ≥ 18 years of age (or ≥ legal adult age within country if it is older than 18 years) at time of signing informed consent.
* Participants with histologically or cytologically confirmed ES-SCLC that progressed or recurred following at least one line of platinum-based anti-cancer therapy for SCLC.

Note: Participants with prior treatment for LS-SCLC should have also received another regimen for their recurrent, ES-SCLC disease.

* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
* Participants must have adequate organ function (cardiac, pulmonary, kidney, and liver).
* Participants must be able to have SC injections administered in the abdomen.
* Participants without measurable disease or tumor tissue (fresh biopsy or archival) available may be permitted after discussion with and approval by Amgen Medical Monitor.

Exclusion Criteria:

* Participants that have received prior DLL3 targeted therapy.
* Participants with untreated or symptomatic brain metastases or those requiring therapy with steroids.
* Note: Participants with asymptomatic brain metastatic lesions are allowed following definitive treatment (Amgen Medical Monitor may approve untreated, asymptomatic brain metastasis if local therapy is not required per investigator judgment).
* Participants with leptomeningeal disease.
* Participants with baseline oxygen requirement.

Where it's running

• University of Southern California, Norris Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting
• University of Illinois Chicago
  Chicago, Illinois, United States Recruiting
• Trinity Health Saint Joseph Mercy Ann Arbor
  Ann Arbor, Michigan, United States Recruiting
• Avera Cancer Institute
  Sioux Falls, South Dakota, United States Recruiting
• University of Texas MD Anderson Cancer Center
  Houston, Texas, United States Recruiting
• Swedish Cancer Institute
  Seattle, Washington, United States Recruiting

Study contacts

• Study coordinator: Amgen Call Center
• Email: medinfo@amgen.com
• Phone: 866-572-6436

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tarlatamab plus AB248 for extensive-stage small cell lung cancer (DeLLphi-311)

  This trial tests whether combining tarlatamab with AB248 is safe and tolerable for adults whose extensive-stage small cell lung cancer has progressed after prior therapy.

  Recruiting at 18 sites Phase 1 Amgen · Gilbert, Arizona and 18 other locations · NCT07037758

• Tarlatamab in strong-performance-status small-cell lung cancer

  This trial tests whether tarlatamab can help people with extensive-stage small-cell lung cancer and poor health (ECOG 2) who have already had prior treatment.

  Recruiting at 8 sites Phase 2 AIO-Studien-gGmbH · Berlin and 7 other locations · NCT07803848

• QLC5508 plus QL2107 vs tislelizumab plus platinum chemotherapy as first treatment for extensive-stage small cell lung cancer

  This phase 3 trial tests whether QLC5508 with QL2107 works better than tislelizumab with platinum chemotherapy for adults with untreated extensive-stage small cell lung cancer.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Shanghai · NCT07802821

• Tarlatamab given under the skin vs by IV in extensive-stage small cell lung cancer after platinum therapy

  This trial tests whether subcutaneous tarlatamab works as well as the IV form for people with extensive-stage small cell lung cancer after platinum chemotherapy.

  Recruiting at 9 sites Phase 3 Amgen · Orlando, Florida and 8 other locations · NCT07778316

• BL-M14D1 with Atezolizumab for extensive-stage small cell lung cancer

  This phase 2 trial tests whether adding BL-M14D1 to atezolizumab helps people with extensive-stage small cell lung cancer live longer or well enough to continue treatment.

  Recruiting Phase 2 Biokin (Shanghai) Biopharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07654400

• Tislelizumab use in European patients with NSCLC or ES-SCLC in routine care

  This study looks at how tislelizumab is used in real-world European patients with advanced NSCLC or extensive-stage SCLC and what outcomes are seen in everyday clinical practice.

  Recruiting at 6 sites BeOne Medicines · Córdoba and 5 other locations · NCT07652736

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.